Belatacept Biosimilar Nulojix, CTLA-4 Fc Fusion Protein

Catalog #: bp-50577

Overview

Belatacept (trade name Nulojix, Bristol-Myers-Squibb), a fusion protein of a Fc fragment (human IgG1 isotype) and the extracellular domain of CTLA-4, can be used to extend graft survival while limiting the toxicity generated by standard immune suppressing regimens, such as calcineurin inhibitors. Belatacept differs from abatacept (trade name Orencia) by only 2 amino acids. The CTLA-4 protein is important for T-cell costimulation and selectively blocks the process of T-cell activation.

Product Details
Species Reactivity	Human
Source	The Nulojix biosimilar CHO stable cell line
Host/Isotype	Human immunoglobulin gamma 1 (hIgG1)
Class	Monoclonal
Type	Antibody
Immunogen	The human CD80 (B7-1) with more avidity than to CD86 (B7-2)
Clone	Belatacept Biosimilar
Conjugate	Unconjugated
Purity	>95%
Molecular Weight	90 kDa
Protein Concentration	1 mg/ml
Formulation	Liquid
Storage Condition	4°C for short time, -20°C or -80°C for long time.
Storage Buffer	0.2 uM filtered PBS solution, pH 7.2-7.8

Images
Datasheets and Documents

Datasheet BP-50577.pdf

Belatacept Biosimilar Nulojix, CTLA-4 Fc Fusion Protein

Belatacept Biosimilar Nulojix, CTLA-4 Fc Fusion Protein

Would you like to inquire about custom quantity?

Overview

Images

Datasheets and Documents

Other Related Products

Trastuzumab (Anti-HER2)

Gemtuzumab (Anti-Siglec-3 / CD33)

Disitamab (Anti-ERBB2 / HER2 / CD340)

Belantamab (Anti-TNFRSF17 / BCMA / CD269)